Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $5.05 million. The enterprise value is -$1.21 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 7.21 million shares outstanding. The number of shares has increased by 64.15% in one year.
| Current Share Class | 7.21M |
| Shares Outstanding | 7.21M |
| Shares Change (YoY) | +64.15% |
| Shares Change (QoQ) | +40.03% |
| Owned by Insiders (%) | 2.82% |
| Owned by Institutions (%) | 4.43% |
| Float | 7.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.57 |
| Forward PS | n/a |
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.07
| Current Ratio | 6.07 |
| Quick Ratio | 5.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,019.15 |
Financial Efficiency
Return on equity (ROE) is -90.03% and return on invested capital (ROIC) is -59.38%.
| Return on Equity (ROE) | -90.03% |
| Return on Assets (ROA) | -43.96% |
| Return on Invested Capital (ROIC) | -59.38% |
| Return on Capital Employed (ROCE) | -92.21% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.63M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.09% in the last 52 weeks. The beta is 1.63, so Silo Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -46.09% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 53.99 |
| Average Volume (20 Days) | 539,003 |
Short Selling Information
The latest short interest is 67,438, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 67,438 |
| Short Previous Month | 134,766 |
| Short % of Shares Out | 0.94% |
| Short % of Float | 0.96% |
| Short Ratio (days to cover) | 0.77 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$4.90 million in losses. Loss per share was -$1.00.
| Revenue | 72,102 |
| Gross Profit | 66,264 |
| Operating Income | -5.17M |
| Pretax Income | -3.60M |
| Net Income | -4.90M |
| EBITDA | n/a |
| EBIT | -5.17M |
| Loss Per Share | -$1.00 |
Full Income StatementBalance Sheet
The company has $6.26 million in cash and n/a in debt, giving a net cash position of $6.26 million or $0.87 per share.
| Cash & Cash Equivalents | 6.26M |
| Total Debt | n/a |
| Net Cash | 6.26M |
| Net Cash Per Share | $0.87 |
| Equity (Book Value) | 4.92M |
| Book Value Per Share | 0.57 |
| Working Capital | 5.32M |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.19M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 91.90% |
| Operating Margin | -7,164.96% |
| Pretax Margin | -6,789.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |